# OnCo record paper-pembrolizumab-glioblastoma-clin-cancer-res-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-pembrolizumab-glioblastoma-clin-cancer-res-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-pembrolizumab-glioblastoma-clin-cancer-res-2021" ;
  schema:name "Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma"@en ;
  schema:description "Phase 2 or 3 results paper on Pembrolizumab in Glioma & glioblastoma, in Clinical Cancer Research (2021), one of the most cited Europe PMC records with Pembrolizumab in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-pembrolizumab-glioblastoma-clin-cancer-res-2021/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/1078-0432.ccr-20-2500>, <https://pubmed.ncbi.nlm.nih.gov/33199490/>, <https://europepmc.org/article/MED/33199490> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1158/1078-0432.ccr-20-2500> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Nayak L, Molinaro AM, Peters K, et al." ;
  onco:journals <https://onco.cc/journals/clinical-cancer-research/> .